| Literature DB >> 30395644 |
Muhammad Awidi1, Hisham Bawaneh2, Hadil Zureigat3, Muna AlHusban3, Abdalla Awidi1,2,3.
Abstract
OBJECTIVES: This study aimed to understand the impact of iron deficiency anemia in female users of a hematology service in a developing country.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30395644 PMCID: PMC6218028 DOI: 10.1371/journal.pone.0205868
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Patient characteristics at presentation.
| Patients Attributes | Results |
|---|---|
| Mean age, ±SD (range), years | 41∙4 ± 17∙3(14–82) |
| Mean Hemoglobin concentration ±SD (range), g/dL | 8∙54 ± 1∙5(4∙4–11∙9) |
| Previously pregnant (n = 101) | |
| Mean Gravida ±SD, (range), (n = 101) | 6 ±2∙5, (1–11) |
| Mean Parity ±SD, (range), (n = 100) | 5 ± 2∙2 (1–11) |
| No comorbidities, n (%) | 100 (48∙07) |
| Smoking status (n = 208) | |
| Smokers (n = 15), % | 7∙2 |
| Non-smokers (n = 193), % | 92∙8 |
| Comorbidities | |
| Endocrine (n = 43) | 20∙67 |
| Cardiovascular (n = 38) | 18∙27 |
| Musculoskeletal (n = 7) | 3∙37 |
| Gastrointestinal (n = 5) | 2∙4 |
| Pulmonary (n = 5) | 2∙4 |
| Others (n = 10) | 4∙81 |
| Menses | |
| Regular (n = 48) | 25∙53 |
| Heavy (n = 84) | 44∙68 |
| Very heavy (n = 56) | 29∙79 |
| Nutrition (n = 185), % | |
| Very poor (n = 34) | 18∙38 |
| Poor (n = 101) | 54∙59 |
| Balanced (n = 50) | 27∙03 |
1Endocrine:Hypothyroid,Diabetes Mellitus, Dyslipidemia
Cardiovascular: Hypertension, atrial fibrillation, Deep Vein Thrombosis, ischemic heart disease cardiomyopathy
Musculoskeletal: Rheumatoid arthritis, Sjogren syndrome, Systemic Lupus Erythematosus, Knee osteoarthritis, osteoporosis and Familial Mediterranean Fever
Gastrointestinal: Gastric ulcers, Hepatitis B and Ulcerative Colitis
Pulmonary: Asthma, Lung fibrosis
Others: Thalassemia minor, chronic kidney disease, epilepsy, migraine and cerebrovascular events
2 20 patients were post-menopausal and didn’t report menses
Laboratory evaluation at initial presentation, anemia severity defined based on hemoglobin (Hb) concentration using WHO anemia classification (mild:11–11.9, moderate:8–10.9, severe: less than 8).
| Laboratory parameter | Value at initial presentation |
|---|---|
| Hemoglobin concentration, g/dL (n = 208) | 8∙47 (7.38–9.70) |
| Anemia Severity (n = 208), % | |
| Mild (n = 13) | 6∙25% |
| Moderate (n = 115) | 55∙29% |
| Severe (n = 80) | 38∙46% |
| Mean corpuscular volume, fL (n = 208) | 66.4 (62.50–72.15) |
| Red cell distribution width, CV % (n = 208) | 18.95 (17.3–20.8) |
| Platelet count, 103/μL (n = 208) | 333.5 (268.5–404) |
| Serum ferritin, ng/mL (n = 208) | 6.67 (4.01–13.30) |
| Iron, μg/dL (n = 172) | 20.45 (16.32–26.96) |
| Total iron binding capacity, μg/dL (n = 163) | 392 (358–431) |
| Serum B12, pg/mL, (n = 183) | 298 (229–414) |
| Serum Folate, ng/mL, (n = 156) | 7.30 (5.00–10.65) |
| Lactate dehydrogenase, U/L, (n = 136) | 346 (310–414.50) |
| Fecal occult blood test (n = 60), % | |
| Positive (n = 10) | 16∙66% |
| Negative (n = 50) | 83∙33% |
| Anti-transglutaminase antibodies (ATA), (n = 41), % | |
| Positive (n = 9) | 21∙95% |
| Negative (n = 32) | 78∙05% |
| Tissue Transglutaminase (tTG) Antibodies, IgA, (n = 75), % | |
| Positive (n = 9) | 12∙00% |
| Negative (n = 66) | 88∙00% |
| Tissue Transglutaminase (tTG) Antibodies, IgG, (n = 62), % | |
| Positive (n = 5) | 8∙06% |
| Negative (n = 57) | 91∙94% |
* Median (Interquartile range)
Etiology and treatment of anemia, Intravenous (IV) formulation was given as ferrous sucrose or iron dextran complex or ferric carboxymaltose, Oral treatment was either ferrous gluconate or ferrous sulfate.
| Hemoglobin concentration categories | P value | |||
|---|---|---|---|---|
| Mild | Moderate | Severe | ||
| Etiology of anemia (n = 200) | ||||
| Menses (n = 38) | 3, (7.89) | 23, (60.53) | 12, (31.58) | 0.61 |
| Nutrition (n = 24) | 1, (4.17) | 15, (62.5) | 8, (33.33) | 0.73 |
| Gastrointestinal (n = 18) | 3, (16.67) | 8, (44.44) | 7, (38.89) | 0.15 |
| Malignancy (n = 3) | 0, (0) | 1, (33.33) | 2, (6.67) | 0.58 |
| Combined (n = 117) | 6, (5.13) | 66, (56.41) | 45, (38.46) | 0.74 |
| Menses Severity (n = 188) | ||||
| Regular (n = 48) | 2, (4.17) | 22, (45.83) | 24, (50) | 0.027 |
| Heavy (n = 84) | 7, (8.33) | 43, (51.19) | 34, (40.48) | |
| Very heavy (n = 56) | 2, (3.57) | 41, (73.21) | 13, (23.21) | |
| Treatment (n = 208) | ||||
| IV (n = 147) | 7, (4.76) | 71, (48.3) | 69, (46.94) | <0.01 |
| Oral (n = 61) | 6, (9.84) | 44, (72.13) | 11 (18.03) | |
| Gravida | ||||
| None (n = 107) | 5, (4.67) | 60, (56.07) | 42, (39.25) | 0.85 |
| Multigravida (n = 31) | 2, (6.45) | 16, (51.61) | 13 (41.94) | |
| Grand multigravida | 6, (8.57) | 39, (55.71) | 25 (35.71) | |
| Parity | ||||
| None (n = 108) | 5, (4.63) | 61, (56.48) | 42, (38.89) | 0.56 |
| Multiparous (n = 43) | 5, (11.63) | 21, (48.84) | 17, (39.53) | |
| Grand multiparous (n = 57) | 3, (5.26) | 33, (57.89) | 21, (36.84) | |
1 WHO anemia classification: Severe (<8 g/dL), Moderate (10–9.8 g/dL), Mild (11.9–11 g/dL)
2 Multigravida defined as <5 pregnancies, Gran multigravida as ≥ 5 pregnancies
3 Multipara defined as <5 pregnancies after 20 weeks of gestation, Grand multiparous as ≥5 pregnancies after 20 weeks gestation